Compare GKOS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | KRYS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.3B |
| IPO Year | 2015 | 2017 |
| Metric | GKOS | KRYS |
|---|---|---|
| Price | $116.08 | $239.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $125.54 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 865.8K | 326.2K |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | N/A | ★ 6.66 |
| Revenue | ★ $469,820,000.00 | $373,164,000.00 |
| Revenue This Year | $31.15 | $36.14 |
| Revenue Next Year | $24.15 | $41.80 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | 30.38 | ★ 54.51 |
| 52 Week Low | $73.16 | $122.80 |
| 52 Week High | $163.71 | $248.60 |
| Indicator | GKOS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 76.42 | 67.80 |
| Support Level | $105.88 | $231.69 |
| Resistance Level | $116.72 | $248.60 |
| Average True Range (ATR) | 3.26 | 8.08 |
| MACD | 0.07 | -0.51 |
| Stochastic Oscillator | 94.61 | 75.49 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.